Yissum was founded in 1964 to protect the Hebrew University's intellectual property and commercialise it. $1 billion in annual sales are generated by products based on Hebrew University technologies licensed out by Yissum. Ranked among the top technology transfer companies in the world, Yissum has registered 5,000 patents covering 1,400 inventions; licensed out 400 technologies and spun out 60 companies. Yissum's business partners span the globe and include companies such as Novartis, Microsoft, Johnson & Johnson, Merck, Intel and Teva.
The information contained in this document is as of December 5, 2007.
Amarin assumes no obligation to update any forward-looking statements
contained in this document as a result of new information or future events
or developments. This document contains forward-looking statements about
Amarin's financial condition, results of operations, business prospects and
products in research that involve substantial risks and uncertainties. You
can identify these statements by the fact that they use words such as
"will", "anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe" and other words and terms of similar meaning in
connection with any discussion of future operating or financial performance
or events. Among the factors that could cause actual results to differ
materially from those described or projected herein are the following:
risks relating to the Company's ability to maintain its Nasdaq listing
(including the risk that the Company may not successfully appeal a Nasdaq
delisting determination); the Company's ability to close the equity,
convertible debt and warrant financings; the Company's ability to
successfully integrate the Ester acquisition; Amarin's ability to maintain
sufficient cash and other liquid resources to
|SOURCE Amarin Corporation Plc|
Copyright©2007 PR Newswire.
All rights reserved